Common Stock, par value $0.001 per share
- Symbol
- NXL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Nexalin Technology, Inc.
NXLNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events On September 30, 2026, Nexalin Technology, Inc. (the “Company”) received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed on The Nasdaq Capital Market to maintain a closing bid price of at least $1.00 per share (the “Minimum Bid Price Requirement”).…
Company context
We are a medical device company engaged in the design and development of innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device.
Current securities
Historical securities (1)
Registered securities in this filing
NEXALIN TECHNOLOGY, INC. · 8-K · Filed 2026-10-01
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events
On September 30, 2026, Nexalin Technology, Inc. (the “Company”)
received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance
with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed on The Nasdaq Capital Market to maintain a closing bid price of at
least $1.00 per share (the “Minimum Bid Price Requirement”).
As previously reported in the Company’s Current Report on Form
8-K filed with the Securities and Exchange Commission on September 28, 2026, on September 25, 2026, the Company received a written notification
(the “Notice”) from the Hearings Panel of the Nasdaq (the “Panel”) granting the Company’s request for continued
listing on Nasdaq, subject to the conditions that (1) on or before September 28, 2026, the Company shall demonstrate compliance with the
Minimum Bid Price Requirement and (2) on or before January 4, 2027, the Company shall demonstrate compliance with the minimum stockholders’
equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’
Equity Requirement”).
The Company intends to take all steps necessary to satisfy the Stockholders’
Equity Requirement on or before January 4, 2027, as required by the Notice, and the Company’s common stock will continue to be listed
and traded on The Nasdaq Capital Market during the exception period granted by the Panel, subject to the Company’s compliance with
the terms of the Notice. There can be no assurance, however, that the Company will be able to demonstrate compliance with the Stockholders’
Equity Requirement by January 4, 2027, or that the Company will otherwise maintain compliance with the Minimum Bid Price Requirement or
the other applicable Nasdaq continued listing requirements. If the Company fails to demonstrate compliance with the Stockholders’
Equity Requirement on or before January 4, 2027, or otherwise fails to comply with the terms of the Notice, the Company’s common
stock will be subject to delisting from Nasdaq.